Inovio Pharmaceuticals Inc (INO)
4.06
+0.09
(+2.27%)
USD |
NASDAQ |
Nov 21, 16:00
4.065
0.00 (0.00%)
After-Hours: 20:00
Inovio Pharmaceuticals Enterprise Value: 21.16M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 21.16M |
| November 20, 2024 | 18.81M |
| November 19, 2024 | 20.38M |
| November 18, 2024 | 21.55M |
| November 15, 2024 | 26.51M |
| November 14, 2024 | 39.69M |
| November 13, 2024 | 44.39M |
| November 12, 2024 | 49.37M |
| November 11, 2024 | 54.32M |
| November 08, 2024 | 59.53M |
| November 07, 2024 | 59.00M |
| November 06, 2024 | 62.91M |
| November 05, 2024 | 61.61M |
| November 04, 2024 | 59.00M |
| November 01, 2024 | 57.18M |
| October 31, 2024 | 52.75M |
| October 30, 2024 | 60.05M |
| October 29, 2024 | 60.05M |
| October 28, 2024 | 62.91M |
| October 25, 2024 | 61.09M |
| October 24, 2024 | 62.65M |
| October 23, 2024 | 63.69M |
| October 22, 2024 | 63.69M |
| October 21, 2024 | 64.74M |
| October 18, 2024 | 61.35M |
| Date | Value |
|---|---|
| October 17, 2024 | 62.91M |
| October 16, 2024 | 64.74M |
| October 15, 2024 | 60.57M |
| October 14, 2024 | 63.69M |
| October 11, 2024 | 65.00M |
| October 10, 2024 | 56.14M |
| October 09, 2024 | 58.22M |
| October 08, 2024 | 63.43M |
| October 07, 2024 | 54.06M |
| October 04, 2024 | 59.79M |
| October 03, 2024 | 62.39M |
| October 02, 2024 | 62.65M |
| October 01, 2024 | 61.61M |
| September 30, 2024 | 65.78M |
| September 27, 2024 | 41.73M |
| September 26, 2024 | 32.64M |
| September 25, 2024 | 32.90M |
| September 24, 2024 | 43.68M |
| September 23, 2024 | 42.12M |
| September 20, 2024 | 57.83M |
| September 19, 2024 | 63.28M |
| September 18, 2024 | 65.36M |
| September 17, 2024 | 65.62M |
| September 16, 2024 | 66.66M |
| September 13, 2024 | 66.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-105.65M
Minimum
Jun 28 2023
4.820B
Maximum
Jun 29 2020
674.67M
Average
250.73M
Median
Dec 13 2019
Enterprise Value Benchmarks
| Novavax Inc | 547.62M |
| Baxter International Inc | 28.43B |
| AIM ImmunoTech Inc | 9.017M |
| Protalix BioTherapeutics Inc | 94.82M |
| Armata Pharmaceuticals Inc | 166.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.17M |
| Total Expenses (Quarterly) | 27.35M |
| EPS Diluted (Quarterly) | -0.89 |
| Earnings Yield | -110.1% |
| Normalized Earnings Yield | -116.41 |